Identification of Cell Surface Antigen Expression in Canine Hepatocellular Carcinoma Cell Lines

Fujimoto, Ayumi; Neo, Sakurako; Ishizuka, Chinatsu; Kato, Takashi; Segawa, Kazuhito; Kawarai, Shinpei; Ogihara, Kikumi; Hisasue, Masaharu; Tsuchiya, Ryosuke

doi:10.1292/jvms.12-0549

Cited by 11 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In HCC, β1-integrin is necessary for cell migration17 and protects tumor cells from chemotherapy-induced apoptosis18. Recently, β1-integrin was identified as a suitable marker in HCC identification, classification, prevention and treatment1920.…”

mentioning

confidence: 99%

Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway

Bai

Wang

Guo

et al. 2014

Sci Rep

View full text Add to dashboard Cite

Prostaglandin E2 (PGE2) has been implicated in cell invasion in hepatocellular carcinoma (HCC), via increased β1-integrin expression and cell migration; however, the mechanism remains unclear. PGE2 exerts its effects via four subtypes of the E prostanoid receptor (EP receptor 1–4). The present study investigated the effect of EP1 receptor activation on β1-integrin expression and cell migration in HCC. Cell migration increased by 60% in cells treated with 17-PT-PGE2 (EP1 agonist), which was suppressed by pretreatment with a β1-integrin polyclonal antibody. PGE2 increased β1-integrin expression by approximately 2-fold. EP1 receptor transfection or treatment with 17-PT-PGE2 mimicked the effect of PGE2 treatment. EP1 siRNA blocked PGE2-mediated β1-integrin expression. 17-PT-PGE2 treatment induced PKC and NF-κB activation; PKC and NF-κB inhibitors suppressed 17-PT-PGE2-mediated β1-integrin expression. FoxC2, a β1-integrin transcription factor, was also upregulated by 17-PT-PGE2. NF-κB inhibitor suppressed 17-PT-PGE2-mediated FoxC2 upregulation. Immunohistochemistry showed p65, FoxC2, EP1 receptor and β1-integrin were all highly expressed in the HCC cases. This study suggested that PGE2 upregulates β1-integrin expression and cell migration in HCC cells by activating the PKC/NF-κB signaling pathway. Targeting PGE2/EP1/PKC/NF-κB/FoxC2/β1-integrin pathway may represent a new therapeutic strategy for the prevention and treatment of this cancer.

show abstract

mentioning

confidence: 99%

Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway

Bai

Wang

Guo

et al. 2014

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In this study, we evaluated two HCC cell lines, 95-1044 (a fast-proliferating cell line) and AZACH (an intermediate-proliferating cell line) [12,44]. Cell lines were preserved using a CultureSure freezing medium and stored in liquid nitrogen (Wako Pure Chemical Industries, Ltd., Osaka, Japan).…”

Section: Cell Lines and Cell Culturementioning

confidence: 99%

Novel Y RNA-Derived Fragments Can Differentiate Canine Hepatocellular Carcinoma from Hepatocellular Adenoma

Ushio,

Hasan,

Arif

et al. 2023

Animals

View full text Add to dashboard Cite

Hepatocellular carcinomas (HCC) are common tumors, whereas hepatocellular adenomas (HCA) are rare, benign tumors in dogs. The aberrant expression of noncoding RNAs (ncRNAs) plays a pivotal role in HCC tumorigenesis and progression. Among ncRNAs, micro RNAs have been widely researched in human HCC, but much less widely in canine HCC. However, Y RNA-derived fragments have yet to be investigated in canine HCC and HCA. This study targeted canine HCC and HCA patients. We used qRT-PCR to determine Y RNA expression in clinical tissues, plasma, and plasma extracellular vesicles, and two HCC cell lines (95-1044 and AZACH). Y RNA was significantly decreased in tissue, plasma, and plasma extracellular vesicles for canine HCC versus canine HCA and healthy controls. Y RNA was decreased in 95-1044 and AZACH cells versus normal liver tissue and in AZACH versus 95-1044 cells. In plasma samples, Y RNA levels were decreased in HCC versus HCA and Healthy controls and increased in HCA versus Healthy controls. Receiver operating characteristic analysis showed that Y RNA could be a promising biomarker for distinguishing HCC from HCA and healthy controls. Overall, the dysregulated expression of Y RNA can distinguish canine HCC from HCA. However, further research is necessary to elucidate the underlying Y RNA-related molecular mechanisms in hepatocellular neoplastic diseases. To the best of our knowledge, this is the first report on the relative expression of Y RNA in canine HCC and HCA.

show abstract

“…Establishment of canine HCC cell lines provides a valuable tool for studying the biology, molecular characteristics, and potential therapeutic targets of this disease. Since the first canine HCC cell line by Boomkens et al (16), several HCC cell lines have been used to study the expression of HCC markers and stem cell-like properties (17)(18)(19)(20). Sphere-forming cells from a canine HCC cell line display increased stem cell marker expression and chemoresistance, similar to stem cells from human cancers (20).…”

Section: Introductionmentioning

confidence: 99%

Establishment and characterization of six canine hepatocellular carcinoma cell lines

Lee,

Bae,

Kim

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

BackgroundHepatocellular carcinoma (HCC) is the most common malignant liver tumor in dogs. Although surgical resection is a major treatment option for canine HCC, there are no distinct strategies for unresectable tumor subtypes or adjuvant chemotherapy for tumors with positive margins. We aimed to establish and characterize novel HCC cell lines from canine patients.MethodsThe cellular morphology, general growth features and tumorigenicity of the established cell lines were evaluated. We also examined the sensitivity of the cell lines to multi-target tyrosine kinase inhibitors (TKIs).ResultsWe established novel canine HCC cell lines from hepatic tumors and an additional kidney tumor of six canine patients. All cell lines showed colony forming and migratory ability. KU-cHCC-001 and KU-cHCC-001-Kidney, two cell lines exhibiting high epithelial–mesenchymal transition characteristics, showed tumorigenicity in xenografted mice. Toceranib, a veterinary TKI that targets vascular endothelial growth factor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-kit, effectively inhibited the mitogen-activated protein kinase pathway and induced apoptosis. The established canine HCC cell lines showed greater sensitivity to toceranib than to sorafenib, a first-line treatment for human HCC targeting RAF/VEGFR/PDGFR. Sorafenib showed improved anti-tumor effects when co-treated with SCH772984, an extracellular signal-regulated kinase inhibitor.ConclusionOur study suggests new therapeutic strategies for canine HCC, and these cell lines are valuable research materials for understanding HCC tumor biology in both humans and dogs.

show abstract

Identification of Cell Surface Antigen Expression in Canine Hepatocellular Carcinoma Cell Lines

Cited by 11 publications

References 22 publications

Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway

Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway

Novel Y RNA-Derived Fragments Can Differentiate Canine Hepatocellular Carcinoma from Hepatocellular Adenoma

Establishment and characterization of six canine hepatocellular carcinoma cell lines

Contact Info

Product

Resources

About